SPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th

Group 1 - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its Pinnacle Study of poziotinib for lung cancer treatment [3][7] - The lawsuit covers all individuals and entities who purchased or acquired Spectrum securities between March 17, 2022, and September 22, 2022, inclusive [7] - Investors have until September 24, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7] Group 2 - The law firm Bragar Eagel & Squire, P.C. is representing the investors in this class action and encourages those who suffered losses to contact them for more information [4][5] - The firm specializes in representing individual and institutional investors in various types of litigation across state and federal courts [5]